A Single-Arm, Open-Label, Expanded Access Study of Vismodegib (GDC-0449) in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma
Phase of Trial: Phase IV
Latest Information Update: 16 Jun 2017
At a glance
- Drugs Vismodegib (Primary)
- Indications Basal cell cancer
- Focus Expanded access; Therapeutic Use
- Sponsors Genentech
- 03 Feb 2012 Additional lead trial investigator identified as reported by ClinicalTrials.gov.
- 03 Feb 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 04 Nov 2010 Trial phase changed from III to II as reported by ClinicalTrials.gov.